Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
gene therapy
life sciences
spinal muscular atrophy
zolgensma
2
×
adeno-associated virus
alexandria venture investments
altitude life science ventures
american society of gene and cell therapy
arch venture partners
bioinnovation capital
biolabs
boston
boston top stories
boxer capital
chemotherapy
daraprim
deals
dravet syndrome
drug pricing
drugs
ed kaye
encoded therapeutics
epipen
epipens
exome
generation bio
generic drugs
hemophilia
illumina
illumina ventures
insulin
johannes fruehauf
labcentral
life science
martin shkreli
matrix capital management
menlo ventures
mylan
What
long
2
×
biotech
crude
cutting
despite
driving
drug
edge
effects
encoded
gene
good
healthcare
help
history
illumina’s
improved
industry
innovation
innovations
investment
lasting
life
limited
limits
medical
medicine
nabs
outcomes
pricing
progress
promising
proud
public
push
remains
sciences
single
therapy
therapy’s
Language
unset
Current search:
zolgensma
×
long
×
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
